These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22945870)

  • 1. B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.
    Schwab I; Seeling M; Biburger M; Aschermann S; Nitschke L; Nimmerjahn F
    Eur J Immunol; 2012 Dec; 42(12):3302-9. PubMed ID: 22945870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.
    Schwab I; Biburger M; Krönke G; Schett G; Nimmerjahn F
    Eur J Immunol; 2012 Apr; 42(4):826-30. PubMed ID: 22278120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.
    Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR
    Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of intravenous immunoglobulins.
    Baerenwaldt A; Biburger M; Nimmerjahn F
    Expert Rev Clin Immunol; 2010 May; 6(3):425-34. PubMed ID: 20441428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.
    Schwab I; Mihai S; Seeling M; Kasperkiewicz M; Ludwig RJ; Nimmerjahn F
    Eur J Immunol; 2014 May; 44(5):1444-53. PubMed ID: 24505033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiinflammatory IgG.
    Kaveri SV; Lacroix-Desmazes S; Bayry J
    N Engl J Med; 2008 Jul; 359(3):307-9. PubMed ID: 18635437
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.
    Washburn N; Schwab I; Ortiz D; Bhatnagar N; Lansing JC; Medeiros A; Tyler S; Mekala D; Cochran E; Sarvaiya H; Garofalo K; Meccariello R; Meador JW; Rutitzky L; Schultes BC; Ling L; Avery W; Nimmerjahn F; Manning AM; Kaundinya GV; Bosques CJ
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1297-306. PubMed ID: 25733881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
    Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH
    J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic intravenous immunoglobulins.
    Lemieux R; Bazin R; Néron S
    Mol Immunol; 2005 May; 42(7):839-48. PubMed ID: 15829272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD22 and autoimmune disease.
    Dörner T; Shock A; Smith KG
    Int Rev Immunol; 2012 Oct; 31(5):363-78. PubMed ID: 23083346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura.
    Jin F; Balthasar JP
    Hum Immunol; 2005 Apr; 66(4):403-10. PubMed ID: 15866704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP.
    Leontyev D; Katsman Y; Branch DR
    Blood; 2012 May; 119(22):5261-4. PubMed ID: 22508937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model.
    Wöhner M; Born S; Nitschke L
    Eur J Immunol; 2012 Nov; 42(11):3009-18. PubMed ID: 22965838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjugation of methotrexate to immunoglobulins kills macrophages by Fc receptor mediated uptake?
    Wang X; Yao C; Jiang Z
    Int J Lab Hematol; 2008 Jun; 30(3):185-90. PubMed ID: 18479295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction.
    Katsman Y; Foo AH; Leontyev D; Branch DR
    Transfusion; 2010 Jun; 50(6):1285-94. PubMed ID: 20088841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiinflammatory activity of IgG: the intravenous IgG paradox.
    Nimmerjahn F; Ravetch JV
    J Exp Med; 2007 Jan; 204(1):11-5. PubMed ID: 17227911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer.
    Lewis BJB; Ville J; Blacquiere M; Cen S; Spirig R; Zuercher AW; Käsermann F; Branch DR
    BMC Immunol; 2019 Dec; 20(1):44. PubMed ID: 31801459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.
    Cen SY; Branch DR
    Transfusion; 2020 Feb; 60(2):250-255. PubMed ID: 31837028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of anti-inflammatory activity of intravenous immunoglobulin via inhibitory Fcgamma receptors.
    Maródi L
    Pediatr Res; 2001 Nov; 50(5):551. PubMed ID: 11641444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.